Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II Trial of Interleukin-12 Followed by Interferon Alfa-2b in Patients with Metastatic Malignant Melanoma: Results from CALGB 500001 (Alliance).

Cancer immunology research·2026
Same author

Tumor Cell-Intrinsic Decr2 Regulates Ferroptosis and Immunotherapy Efficacy.

Cancer immunology research·2025
Same author

Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma.

Nature medicine·2025
Same author

Author Correction: Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours.

Nature·2025
Same author

Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.

Blood advances·2025
Same author

PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid Cells.

Cancer immunology research·2025
Same journal

Preoperative circulating tumor cells integrated with imaging analysis for prognostic evaluation in head and neck squamous cell carcinoma.

Molecular oncology·2026
Same journal

From tumor-centric to ecosystem-based hypotheses in brain tumor research and care: Proceedings from The second Brain Tumor Meeting by the Sea organized by Julie Gavard and Eric Chevet, held in St Malo (France), 23-25 March 2026.

Molecular oncology·2026
Same journal

Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation.

Molecular oncology·2026
Same journal

In vitro and in silico modelling of ROS1-positive non-small cell lung cancer reveals fusion-dependent tyrosine kinase inhibitor responses.

Molecular oncology·2026
Same journal

The role of miR-335-5p in the redifferentiation of BRAF p.V600E thyroid cancers.

Molecular oncology·2026
Same journal

EXPRESSION OF CONCERN: A Newly Identified 45-kDa JAK2 Variant with an Altered Kinase Domain Structure Represents a Novel Mode of JAK2 Kinase Inhibitor Resistance.

Molecular oncology·2026
See all related articles

Related Experiment Video

Updated: May 25, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Cancer immunotherapy.

Thomas F Gajewski1

  • 1University of Chicago, Chicago, IL 60637, USA. tgajewsk@medicine.bs.uchicago.edu

Molecular Oncology
|January 18, 2012
PubMed
Summary
This summary is machine-generated.

Cancer immunotherapies are advancing from non-specific agents to targeted treatments. Identifying tumor-specific antigens and understanding the tumor microenvironment are key to developing effective, personalized cancer vaccines and therapies.

More Related Videos

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Related Experiment Videos

Last Updated: May 25, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Cancer immunotherapy has evolved from non-specific agents like cytokines to targeted approaches.
  • Molecular identification of cancer-associated antigens enables specific vaccines and adoptive T cell therapies.
  • Recent advances allow identification of patient-specific tumor epitopes from somatic mutations.

Purpose of the Study:

  • To explore the potential of antigen recognition in developing specific immune-based cancer therapies.
  • To investigate the role of tumor microenvironment phenotypes and immune suppressive factors in immunotherapy response.
  • To highlight opportunities for personalized cancer immunotherapy.

Main Methods:

  • Analysis of cancer-associated antigens and patient tumor-specific epitopes.
  • Transcriptional profiling and immunohistochemistry to assess the tumor microenvironment.
  • Identification of immune suppressive factors within tumors.

Main Results:

  • Patient-specific tumor antigens can be identified using exome sequencing.
  • A T cell-inflamed tumor microenvironment may predict immunotherapy response and serve as a biomarker.
  • Targeting identified immune suppressive factors shows promise in early clinical trials.

Conclusions:

  • Personalized cancer immunotherapy is increasingly feasible through the identification of tumor-specific antigens.
  • The tumor microenvironment and its suppressive factors are critical targets for novel immunotherapeutics.
  • A deeper understanding of tumor-host immune dynamics opens new avenues for effective cancer treatment.